TYRA
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2656 State St, Carlsbad, California, 920...Phone Number
(619) 728-4760Website
tyra.bioRevenue
$104.2 MillionStock Symbol
TYRAIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
2
About TYRA
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNP, enables the rapid and precise refinement of structural drug design through iterative molecular SNPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.Explore more
TYRA Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TYRA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on TYRA recently announced quarterly report
Check if TYRA has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at TYRA
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when TYRA launches new products
Click to see if TYRA had a recent Job posting/layoffs
Funding: Get notified immidiatlly once TYRA has new funding data
Check out if TYRA is spiking on competitors!
TYRA, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at TYRA
Find more new buyers
Compare Similar Companies to TYRA
Compare insights from companies similar to TYRA, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TYRA is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TYRA is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TYRA.
TYRA financials insights
Gather financial insights about TYRA, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$50M
2021
Series B
$106M
Share Placement
$172.8M
2024
Other Financing Round
$200M
TYRA Tech Stack
A closer look at the technologies used by TYRA
Most Recent Scoops
Hiring Plans
TYRA has more open roles in Legal than it has had at any time in the past 12 months. Technologies mentioned include: Remote.
Hiring Plans
Project
TYRA is conducting SURF302, a signal-seeking Phase II study evaluating two doses of dabogratinib in intermediate-risk NMIBC, with initial efficacy data from approximately 20 evaluable patients expected in August and a 70% three-month complete response rate established as the threshold for dose selection and advancement to Phase III.
Clinical Operations
Project
TYRA has initiated its Phase II UTUC study, with the first patient dosed and sites including MD Anderson and Cleveland Clinic open and screening, targeting initial dose-selection data in 2027 and benchmarking against infigratinib's 67% overall response rate at 12 weeks.
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
TYRA News & Media
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on...Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tyra Biosciences, Inc. (TYRA) Bank of America Global Healthcare Conference 2026 May 13, 2026 1:40 PM EDTCompany ParticipantsTodd Harris - Co-Founder, CEO,...Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 - - Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to...Tyra Biosciences CMO granted RSUs and options | TYRA Insider Trading - Stock Titan
Tyra Biosciences grants its CMO 25,000 RSUs and stock options for 85,000 shares at a $33.93 exercise price, vesting over four years with continued service.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding TYRA
Sign Up For FreeTo access detailed company insights
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNP, enables the rapid and precise refinement of structural drug design through iterative molecular SNPshots th... Read More
